AJCN Tufts Nutrition Symposium, Boston Sept 24-26
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shane, B.
Right arrow Articles by Contractor, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shane, B.
Right arrow Articles by Contractor, S. F.
Agricola
Right arrow Articles by Shane, B.
Right arrow Articles by Contractor, S. F.

American Journal of Clinical Nutrition, Vol 28, 739-747, Copyright © 1975 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Assessment of vitamin B 6 status. Studies on pregnant women and oral contraceptive users

B Shane and SF Contractor

The vitamin B6 status of 10 pregnant women (third trimester), 9 oral contraceptive agent users, and 12 notnpregnant women (controls) was investigated over a 10-week period by means of the erythrocyte glutamate-oxaloacetate transaminase (E-GOT) activation test and by measurements of whole blood pyridoxal phosphate levels. Blood pyridoxal phosphate levels in oral contraceptive agent users (7.6 plus or minus 1.1 ng/ml) were significantly lower than in the control group (9.6 plus or minus 1.7 mg/ml)indicating a relative vitamin B6 deficiency. Pyridoxal phosphate levels in pregnant women(5.1 plus or minus 1.3ng/ml) were even lower; in fact, no overlap was found in individual mean values between the pregnant and control groups. The E-GOT activation test did not indicate a vitamin deficiency in the pregnant women or in oral contraceptive agent users and the E-GOT activation factor did not correlate with blood pyridoxal phosphate levels unless results obtained after pyridoxine hydrochloride (20 mg/day) administration were included. The E-GOT activation test appears to be a poor indicator of vitamin B6 status, except in pronounced deficiency as it is less responsive to vitamin depletion than blood pyridoxal phosphate levels, and suffers from relatively large variations in individual control values. This may be a result of factors unrelated to vitamin B6 as blood pyridoxal phosphate levels remained fairly constant in the individuals investigated.


This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
M. S. Morris, M. F. Picciano, P. F Jacques, and J. Selhub
Plasma pyridoxal 5'-phosphate in the US population: the National Health and Nutrition Examination Survey, 2003-2004
Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1446 - 1454.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1975 by The American Society for Nutrition